Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines.
High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.
Azzarà A, Carulli G, Galimberti S, Baratè C, Fazzi R, Cervetti G, Petrini M.
Nguồn‎: Am J Hematol 2011;86(9):762-7.
Recombinant human erythropoietin is associated with increased overall survival in patients with multiple myeloma.
Baz R, Walker E, Choueiri TK, Abou Jawde R, Brand C, McGowan B, Yiannaki E, Andresen S, Hussein MA.
Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial.
Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F.
Nguồn‎: Am J Hematol 2013;88(12):990-6.
Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.
Blohmer JU, Paepke S, Sehouli J, Boehmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P.
Nguồn‎: J Clin Oncol 2011;29(28):3791-7.
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.
Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.
Management of anemia in cancer patients.
Nguồn‎: Acta Haematol Pol 2007;38(4):479-84.
Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe.
Deger M, Eisterer W, Kutikova L, Salek S.
Nguồn‎: Support Care Cancer 2013;21(2):485-93.
The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer.
Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.
Nguồn‎: J Clin Oncol 2010;28(13):2239-45.
Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses.
Ford PA, Grant SJ, Mick R, Keck G.
Nguồn‎: J Clin Oncol 2015;33(15):1674-9.
Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation.
Fujisaka Y, Sugiyama T, Saito H, Nagase S, Kudoh S, Endo M, Sakai H, Ohashi Y, Saijo N.
Nguồn‎: Br J Cancer 2011;105(9):1267-72.
Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome.
Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Čermák J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellström-Lindberg E.
Nguồn‎: J Intern Med 2017;281(3):284-99.
Update on safety of ESAs in cancer-induced anemia.
Nguồn‎: J Natl Compr Canc Netw 2012;10(5):659-66.
A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes.
Jang JH, Harada H, Shibayama H, Shimazaki R, Kim HJ, Sawada K, Mitani K.
Nguồn‎: Int J Hematol 2015;102(4):401-12.
Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients.
Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trial.
Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz U, Runnebaum IB, Hinke A, Kreienberg R, Untch M; on behalf of the AGO Breast Study Group.
Nguồn‎: J Natl Cancer Inst 2013;105(14):1018-26.
Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.
Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, Okamoto R, Saijo N, Hotta T.
Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.
Nguồn‎: Support Care Cancer 2012;20(1):159-65.
Epoetin alfa improves anemia and anemia-related, patient-reported outcomes in patients with breast cancer receiving myelotoxic chemotherapy: results of a European, multicenter, randomized, controlled trial.
Pronzato P, Cortesi E, van der Rijt CC, Bols A, Moreno-Nogueira JA, de Oliveira CF, Barrett-Lee P, Ostler PJ, Rosso R; for the EPO-INT-47 Study Group.
Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J.
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.
Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G.
Nguồn‎: Eur J Haematol 2016;97(1):33-8.
Nguồn‎: J Natl Compr Canc Netw 2008;6(6):585-92.
Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia.
Calleja JL, Delgado S, Del Val A, Hervás A, Larraona JL, Terán Á, Cucala M, Mearin F; Colon Cancer Study Group.
Nguồn‎: Int J Colorectal Dis 2016;31(3):543-51.
Total dose iron dextran infusion in cancer patients: is it SaFe2+?
Gilreath JA, Stenehjem DD, Rodgers GM.
Nguồn‎: J Natl Compr Canc Netw 2012;10(5):669-76.
Thrombocytosis and venous thromboembolism in cancer patients with chemotherapy induced anemia may be related to ESA induced iron restricted erythropoiesis and reversed by administration of IV iron.
Henry DH, Dahl NV, Auerbach MA.
Nguồn‎: Am J Hematol 2012;87(3):308-10.
Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis-stimulating agent therapy.
The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents.
Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.
Nguồn‎: Cochrane Database Syst Rev 2016;(2):CD009624.
Perioperative anemia management in colorectal cancer patients: a pragmatic approach.
Muñoz M, Gómez-Ramírez S, Martín-Montañez E, Auerbach M.
Nguồn‎: World J Gastroenterol 2014;20(8):1972-85.
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha.
Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.
Nguồn‎: J Clin Oncol 2008;26(10):1619-25.
Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.
Petrelli F, Borgonovo K, Cabiddu M, Lonati V, Barni S.
Nguồn‎: J Cancer Res Clin Oncol 2012;138(2):179-87.
Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.
Steinmetz T, Tschechne B, Harlin O, Klement B, Franzem M, Wamhoff J, Tesch H, Rohrberg R, Marschner N.